ARTS II

ARTS II

Arterial Revascularization Therapy Study part II. A trial comparing the sirolimus-eluting Bx Velocity® Balloon expandable stent in patients with multivessel disease, ischaemia, and no prior coronary interventions.
Primary endpoint 1-year major acute coronary and cerebrovascular events (MACCE) compared with the 1-year MACCE of ARTS I.
Conclusion MACCE is 3% in ARTS II compared to 4% with CABG and 8% with percutaneous coronary intervention in ARTS I.
References in periodicals archive ?
ARTS l'in baypas ve CMS grubu ile ISS uygulanan yeni 225 hastanin karsilastirildigi ARTS II calismasinda major kardiyovaskuler olaylarda fark saptanmazken, bir yilda diger sonuclarda da fark yoktu (31).
Pek cok ISS calismasinda guncel olmayan baypas yontemleri ile stentler karsilastirilirken (orn: ARTS II, ERACI III) bu arastirmada iki stratejinin de es zamanli ve guncel yontemlerle uygulanmis olmasi stentler gibi cerrahi yontem ve tekniklerin de degismis ve gelismis olmasi nedeni ile onemlidir.
The superiority of stenting with sirolimus-eluting stents in ARTS II contrasted with the results of the bare-metal-stent arm of ARTS I.
Full browser ?